Bristol-Myers Squibb

BMY

Market cap $122B

BMY reports positive phase III SUCCESSOR-2 data as mezigdomide combo improves progression-free survival in relapsed multiple myeloma, boosting CELMoD program.

Pharmaceutical outfit Pfizer offers the highest dividend yield to newcomers. Dentsply Sirona, however, will likely produce the fastest dividend growth.

The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock contributors to relative performance. Royal Caribbean and O'Reilly Automotive were among the largest stock detractors from relative performance.

Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma.

The company's "growth portfolio" is offsetting declines in "legacy" treatments. It also showed marked progress in two of its developmental programs.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.

In the latest trading session, Bristol Myers Squibb (BMY) closed at $60.74, marking a -2.55% move from the previous day.

Bristol Myers Squibb can navigate the dreaded patent cliff while maintaining modest dividend growth. Medtronic's strong, innovative business helps support its impressive dividend program.